Comparison of HIV-RNA log 10 (mean ± SD) between cases and controls from baseline to the end of follow-up

<p><b>Copyright information:</b></p><p>Taken from "Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving Highly Active Anti Retroviral Therapy"</p><p>BMC Infectious Diseases 2004;4():46-46.</p><p>Published online 6 Nov 2004</p><p>PMCID:PMC533877.</p><p>Copyright © 2004 Tumbarello et al; licensee BioMed Central Ltd.</p

Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving Highly Active Anti Retroviral Therapy-1

<p><b>Copyright information:</b></p><p>Taken from "Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving Highly Active Anti Retroviral Therapy"</p><p>BMC Infectious Diseases 2004;4():46-46.</p><p>Published online 6 Nov 2004</p><p>PMCID:PMC533877.</p><p>Copyright © 2004 Tumbarello et al; licensee BioMed Central Ltd.</p>control

Survival among patients with <i>Candida</i> bloodstream infection (CBSI) at 30 days.

<p>Patients were grouped according to the biofilm-forming (BF) or non-biofilm-forming (NBF) <i>Candida</i> isolate (for all CBSIs), and according to receiving of highly active anti-biofilm (HAAB) or non-HAAB antifungal therapy (for BF CBSIs only). P-values for statistically significant differences between the groups are shown.</p

Hospital length of stay (LOS) following the <i>Candida</i> bloodstream infection (CBSI) onset in all (white box-plots) or surviving (grey box-plots) patients.

<p>Patients were grouped according to the biofilm-forming (BF) or non-biofilm-forming (NBF) <i>Candida</i> isolate (for all CBSIs), and according to receiving of highly active anti-biofilm (HAAB) or non-HAAB antifungal therapy (for BF CBSIs only). Lines inside the boxes indicate the median values, whereas upper and lower limits of the boxes and whiskers indicate the interquartile and total ranges, respectively. P-values for statistically significant differences between the groups are shown.</p

Logistic regression analysis of risk factors for candidemias by biofilm-forming (BF) and non-biofilm-forming (NBF) isolates.

<p><b>NOTE.</b> CBSI, <i>Candida</i> bloodstream infection; CVC, central venous catheter.</p

Comparison between patients with biofilm-forming (BF) candidemia or non-biofilm-forming (NBF) candidemia in the matched cohort study.

<p><b>NOTE.</b><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0033705#s3" target="_blank">Results</a> are shown as no. (%) or median with range. LOS, length of stay; ICU, intensive care unit; CBSI, <i>Candida</i> bloodstream infection; COPD, chronic obstructive pulmonary disease; HIV, human immunodeficiency virus; CVC, central venous catheter.</p>a<p>Days of hospital stay prior to the onset of candidemia (or, for controls, total days in the hospital).</p>b<p>Number of hospital days from admission to the onset of candidemia (or, for controls, total days in the hospital).</p>c<p>Other species includes <i>Candida krusei</i> (3 cases), <i>Candida lusitaniae</i> (2 cases), and <i>Candida guilliermondii</i> (1 case).</p>d<p>Absolute neutrophil count <500 cells/mm³.</p>e<p>Within 30 days prior to the onset of candidemia (or, for controls, at any point during hospitalization).</p>f<p>Therapeutic failure at 72 h after starting antifungal therapy, as assessed by the persistence of infection or by the occurrence of death.</p

Distribution of variables according to score points in the derivation and validation sets.

<p>Distribution of variables according to score points in the derivation and validation sets.</p

Model and risk score performance: derivation set (n = 247) and validation set (n = 247).

<p>Abbreviations: TP, number of true positives; FP, number of false positives; FN, number of false negatives; TN, number of true negatives; Se, sensitivity; Sp, specificity; PPV, positive predictive value; NPV, negative predictive value; Acc, rate of accuracy of the risk score model.</p

Multivariate logistic regression analysis of risk factors for mortality in patients with bacteremia and hematological malignancies.

<p>Multivariate logistic regression analysis of risk factors for mortality in patients with bacteremia and hematological malignancies.</p

Receiver operator characteristic curves (ROC) for the scoring system in the derivation set, validation set, and combined populations.

<p>Receiver operator characteristic curves (ROC) for the scoring system in the derivation set, validation set, and combined populations.</p